1. ESE – Introduction.

The European Society of Endocrinology (ESE), established in 2006, unites, supports and represents the European community of endocrine clinicians and researchers.

This community consists of more than 22,500 health care providers, that connect with ESE through individual membership or the membership of 54 National Endocrine Societies that are part of the ESE Council of Affiliated Societies (ECAS). ESE works to provide education for all career stages, and across all areas of endocrinology, develop clinical guidelines improving the standards of clinical care, organise the Annual European Congress of Endocrinology (ECE) and aims to impact on European Health policies, with specific focus on hormone health and disease.

For 2021, an important factor impacting on ESE and our members is the ongoing crisis from the COVID-19 pandemic. We have already been adapting our activities to these new circumstances, primarily by developing a digital approach towards our educational provision and the annual congress e-ECE 2020, but also by developing extra initiatives such as webinars around COVID-19 and endocrinology.

The requirements for basic and ongoing education, the need for data sharing around diagnostic and therapeutic innovations, guidance around endocrine diseases, the adoption of new ways of working in hospitals, and the opportunity to impact on a new direction for European Health Policies are all guiding and shaping our plans and activities for 2021.

Our strategic objectives for 2021 are:

- **Enhancing our educational offering to members of all career stages and areas of interest**
- **Augmenting our digital infrastructure with a focus on e-ECE 2021, as well as the overall digital delivery of our activities**
- **Renewing and extending our membership approach to better meet the needs of our communities**
- **Strengthening support to our Focus Areas as drivers of initiatives in the respective endocrine disease areas**
- **Shaping the future of Endocrinology by securing appropriate attention to hormones and endocrine health and disease in the development of new European and National Health Policies**
2. **Corporate Membership**

ESE Corporate Membership is the way for our industry partners to engage with the audiences that ESE represents, and the many programmes we offer to our members and other stakeholders, including patient advocacy and policy.

Corporate Membership allows the Society to fulfil its yearly ambitions, appropriately investment in building the future, and engage in many programmes that are being developed by ESE’s Committees, to the benefit of our members and endocrinologists across Europe and beyond.

Towards our Corporate Members it provides unique opportunities to communicate with the endocrine community in Europe and work in partnership with ESE in the development of new and quality services that ultimately increase excellence in endocrine education and patient care.

Corporate Membership to the European Society of Endocrinology represents:

- Unique access to the endocrine community in 54 countries, representing more than 20,500 endocrinologists and > 4,500 direct members
- Privileged access to the engagement, commercial and educational opportunities offered by the European Congress of Endocrinology. The e-ECE 2020 digital event was attended by 4,675 participants from 112 countries. The digital format of the meeting and inclusion of the content in the digital ESE On Demand platform increases further the reach of the congress into the community.
- Opportunity to work together and support ESE in its educational activities (Post Graduate Courses, Clinical Update meetings and/or webinars, professional development initiatives.
- Regular engagement with the Society Leadership Team and experts to discuss areas of mutual interest that form the basis of the programmes across our eight Focus Areas

**Corporate Membership is open to any company:**

- With a scientific, diagnostic, technical, or clinical focus
- Engaged in education and services for healthcare professionals
- Working in, or associated with, any of our eight Focus Areas of endocrinology
- Developing or commercialising products or services at any stage of their life cycle

**Engagement opportunities offered by Corporate Membership**

The benefits of Corporate Membership are about engagement with the **key audiences** in Europe, and the many programmes ESE has developed.

- Europe’s opinion leaders and endocrine experts
- Leadership of the newly refreshed Focus Areas
- Member communities around specific areas of interest, as represented by the eight Focus Areas
- Young and upcoming endocrinologists as member of EYES (ESE Young Endocrinologists and Scientists)
- Expanding Endocrine Nurse community
- Policy and advocacy stakeholders at European and National level

**Corporate Membership gives our industry partners access to the following forms of engagement opportunities:**

- Satellite symposia and ECE Hub opportunities at the European Congress of Endocrinology, and inclusion in the ESE On Demand platform
• ECE and other event preferential sponsorship options.
• Support of official prizes, grants, awards and travel scholarships
• ESE INSIGHT reports and other community education formats
• Association to bespoke projects of different nature initiated by the ESE Focus Areas
• Association to regional educational course (basic, clinical) and our Clinical Update (physical meetings or webinar formats) initiatives
• Engagement in, and support to, ESE’s Policy and Advocacy efforts

3. **The ESE Corporate Membership 2021 scheme**

**ESE Corporate Membership** (Standard or Premium) offers different levels of engagement and benefits, tailored to the profile of the participating company.

**Premium Corporate Membership** reflects an important and ongoing engagement of your company with ESE, not just related to the annual European Congress of Endocrinology but including a more extensive engagement with the educational initiatives and projects that ESE develops. Premium Corporate Members are part of the Industry Partnership Board, that focusses on longer term collaboration in the area of education, key society initiatives, policy and advocacy work, and the way society and industry can work together.

**Standard Corporate Membership** is a prerequisite to engage with the society around educational initiatives. These can relate to company activities during the annual congress (Satellite Symposium, ECE Hub sessions), or specific support provided to educational events or projects that are of a general nature (e.g. Post Graduate Courses) or specific to the focus areas (Webinars, Clinical Update meetings, expert meetings, surveys).

Corporate Membership also creates the opportunity for engagement with and support to the **Policy and Advocacy efforts** that ESE has been undertaking since 2018. With the increasing momentum at the European level to develop health care and health related research policies across Europe, ESE is intensifying efforts to establish understanding for the role of Hormones in European Health Policies. We engage with consultations issued by the European Commission, provide an expert opinion in health debates and engage with members of the European Parliament and Commission. Through the ESE Council of Affiliated societies with its 54 National endocrine societies, efforts at European level can also be followed through at the National level.

Support to the Policy and Advocacy ambitions of the society can be integrated in an augmented Corporate Membership package or be subject of a separate grant request.

The publication of the ESE White Paper ‘Hormones in European Health Policies’ (planned for early 2021) constitutes a distinct opportunity to support the launch of this White Paper and its distribution.

For more information, please contact Dirk De Rijdt at [dirk.de-rijdt@ese-hormones.org](mailto:dirk.de-rijdt@ese-hormones.org)
The table below provides an overview of membership entitlements and 2021 membership fees. Corporate Membership runs annually January to December. ESE welcomes multi-year commitment from companies to help the Society plan on a longer-term basis.

<table>
<thead>
<tr>
<th>ESE Corporate Membership level</th>
<th>Premium Corporate Member</th>
<th>Corporate Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership fees (2021)</td>
<td>€25,000</td>
<td>€15,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Benefit</th>
<th>Premium Corporate Member</th>
<th>Corporate Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing educational opportunities</td>
<td>1st option</td>
<td>2nd option</td>
</tr>
<tr>
<td>Engagement opportunities with Focus Area educational and other initiatives</td>
<td>1st option</td>
<td>2nd option</td>
</tr>
<tr>
<td>Membership of the Industry Partnership Board (IBP)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>1:1 Leadership meeting</td>
<td>x2 per year</td>
<td>x1</td>
</tr>
<tr>
<td>European Journal of Endocrinology access</td>
<td>x5 medical staff</td>
<td>x2 medical staff</td>
</tr>
<tr>
<td>Focus Area Insight report – a disease area themed publication from ESE</td>
<td>Yes. via grant support</td>
<td>Yes. via grant support</td>
</tr>
<tr>
<td>Insight Industry Meeting report – a industry commissioned report independently written by ESE</td>
<td>Yes. via grant or sponsorship</td>
<td>Yes. via grant or sponsorship</td>
</tr>
<tr>
<td>Acknowledgement in the quarterly member newsletter ESE News</td>
<td>Listing + logo, all issues</td>
<td>Listing only, all issues</td>
</tr>
</tbody>
</table>

**ECE related benefits**:

<table>
<thead>
<tr>
<th>Benefit</th>
<th>Premium Corporate Member</th>
<th>Corporate Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsorship ECE awards and travel grants</td>
<td>1st option</td>
<td>2nd option</td>
</tr>
<tr>
<td>Booking of Satellite symposia, incl. room &amp; time allocation priority</td>
<td>1st option</td>
<td>2nd option</td>
</tr>
<tr>
<td>Booking of ECE Hub, incl. room &amp; time allocation priority</td>
<td>1st option</td>
<td>2nd option</td>
</tr>
<tr>
<td>Sponsorship packages</td>
<td>Can be Platinum Sponsor</td>
<td>Gold-Silver-Bronze</td>
</tr>
</tbody>
</table>

**Policy and Advocacy**

<table>
<thead>
<tr>
<th>Benefit</th>
<th>Premium Corporate Member</th>
<th>Corporate Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support and acknowledgement of support in various Policy and Advocacy initiatives (White Paper, meetings, and such like)</td>
<td>via grant support</td>
<td>via grant support</td>
</tr>
<tr>
<td>Engagement in strategic discussions (part of Industry Partnership Board (IPB))</td>
<td>YES</td>
<td></td>
</tr>
</tbody>
</table>

*additional fees apply. See separate information; priority ranking for exhibit space and satellite symposia includes total industry spending during previous ECE congress

**ESE Supporter Membership:**

**ESE Supporter** Membership is reserved for entities (pharma, diagnostics, services) that are in an early development / pre-commercial phase and / or with limited commercial perspective, that want to start an engagement with ESE and support the organization. Supporter level will be limited to a period of two years only, and can be considered a precursor to an application as Corporate Member. In case the basic criteria for Supporter basis still apply, this period can be extended.
ESE Supporter Membership status comes at an annual membership fee of €5 000.

Supporter status entitles the applicant to the following:

- Acknowledgement of Supporter Status in ESE News (name)
- Free online access to the European Journal of Endocrinology (1 member of medical staff)
- Support and engagement with the ESE educational activities
- Sponsorship opportunity to publish meeting report (independently commissioned)

4. To conclude

ESE Corporate Membership is an attractive engagement for industry partners to connect to the European Society of Endocrinology. The society fosters an open dialogue with its corporate members, and recognises that our corporate members play a pivotal role in our success.

We trust that the access to endocrinology provided through and the services connected to the ESE Corporate Membership will be of benefit to your organisation in 2021.

For more information:

For further information, including contractual arrangements, related to corporate sponsorship and/or the discussion of engagement opportunities, please contact Dirk De Rijdt, Director of Strategic Partnerships at dirk.de-rijdt@ese-hormones.org.

For all sponsorship arrangements related to the 23rd European Congress of Endocrinology May 22-26 2021, please contact Victoria Withy, Sales and Marketing Manager at victoria.withy@ese-hormones.org

For matters related to invoicing of your corporate membership, please contact Liz Stone at info@euro-endo.org.

Dirk De Rijdt
Director of Strategic Partnerships
European Society of Endocrinology
Telephone: +32 478 796734
Email: dirk.de-rijdt@ese-hormones.org
Annex 1: How ESE works with industry

Objectivity and transparency is critical to carrying out ESE’s mission and to maintaining the confidence of its members, the endocrine community and the public; as health and knowledge are highly valuable public benefits, it is of the utmost importance that they are delivered independently.

A Code of Conduct covering both ethical principles and conduct is a necessary underpinning to achieve this, and ESE adheres to the Code of Conduct for Healthcare Professionals and Scientific Organisations in Europe set out by the Alliance for Biomedical Research in Europe Biomed Alliance Code of Conduct, of which ESE is a member – see here. Adoption of this Code reinforces the core principles that help to maintain professional independence, objectivity and scientific integrity.

It is recognized that working with industry is essential to achieve ESE’s mission, and there are clear benefits on both sides, but this must be accomplished without compromising our integrity.

Key principles governing how ESE work with industry are as follows:

1. Any activity must be in line with ESE’s vision, mission and strategic aims – see here.
2. All partnerships will be based on the principles of integrity and openness and will bring benefit to ESE through funding or through supporting ESE to achieve its vision and mission.
3. Any agreements entered into will not compromise the independent status of ESE.
4. ESE will work with members of the pharmaceutical industry to share knowledge and expertise, as appropriate.
5. Multi-sponsor activities will be sought where possible; however in certain circumstances ESE will accept single sponsorship for activities if it is deemed to be in the best interest of those affected by endocrine conditions, as long as the other principles are adhered to.
6. Editorial independence must be maintained so that ESE and its members are free to comment both positively and negatively about pharmaceutical companies and their products.
7. Industry will have no input into the development of ESE scientific, clinical, or educational programmes, unless specifically requested for a valid reason.
8. ESE will not work with industry where promotion of a specific drug is required or demanded by the company (either explicitly or implicitly) and will not endorse any pharmaceutical products or services.
9. Conflicts of interest are always disclosed, recorded, and where deemed appropriate the person declaring the conflict is not included in discussions/votes where the conflict is relevant.